中国癌症杂志 ›› 2017, Vol. 27 ›› Issue (10): 822-828.doi: 10.19401/j.cnki.1007-3639.2017.10.010

• 综述 • 上一篇    下一篇

再议乳腺癌内分泌治疗10项热点问题

王晓迪1,江泽飞2   

  1. 1. 清华大学附属北京清华长庚医院肿瘤内科,北京 102218 ;
    2. 军事医学科学院附属医院乳腺肿瘤科,北京 100071
  • 出版日期:2017-10-30 发布日期:2017-12-05
  • 通信作者: 江泽飞 E-mail:Jiangzf@hotmai.com

Rediscussion on 10 hot issues of endocrine therapy for breast cancer

WANG Xiaodi1, JIANG Zefei2   

  1. 1. Department of Breast Cancer, Beijing Tsinghua Changgung Hospital, Beijing 102218, China; 2. Department of Breast Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China
  • Published:2017-10-30 Online:2017-12-05
  • Contact: JIANG Zefei E-mail: Jiangzf@hotmail.com

摘要: 近年来,乳腺癌的内分泌治疗数据更新较多,使临床工作中产生了新的问题,带来了新的思考。该文就绝经前乳腺癌患者内分泌治疗中卵巢功能抑制的适宜患者的选择,卵巢功能抑制联合口服内分泌药物方案的选择,内分泌治疗过程中不良反应管理,乳腺癌患者的生育问题和延长内分泌治疗等10项早期乳腺癌内分泌治疗中的热点问题,结合数据和笔者的临床经验进行再次阐述。

关键词: 乳腺肿瘤, 内分泌治疗, 治疗

Abstract: With the data generated in recent years, the new issues encountered by practicing physicians in endocrine therapy for breast cancer have been warmly discussed. Meanwhile, the hot discussion brought us new ways of thinking. Based on the new evidence and clinical experience, this article rediscussed the application of ovarian function suppression (OFS) and the appropriate choice of endocrine drugs combining with OFS. We focused on the management of the adverse effects in patients using OFS plus aromatase inhibitor, the fertility problems and prolonged endocrine treatment in breast cancer patients.

Key words: Breast cancer, Endocrine therapy, Treatment